We expect investors to focus on the sales numbers of CRISPR Therapeutics’ CRSP sole-marketed product, Casgevy, and other ...

Prime Medicine’s modular editing tech may lower off-target risk, but key data and funding milestones remain ahead. Find out ...

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid to focus resources on a pair of cancer cell therapies.

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Plant breeding plays a vital role in ensuring global food security by increasing crop yields, improving nutritional quality ...

Bristol Myers Squibb’s new treatment for schizophrenia didn’t provide additional benefits to patients when given on top of ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

CRISPR and CRISPR-Associated Gene Market Set to Surge to $20 Billion by 2035, Fueled by Technological Breakthroughs and Biotech Investments The global CRISPR and CRISPR-Associated Gene Market Size is ...

Latest study leverages new constructs for nuclear localization signal (NLS) sequences to improve editing efficiency in human ...

The Trump administration has reportedly disrupted over 100 clinical trials. Science News spoke to researchers about the impacts on four of them.

Delve into the landscape of biotech companies developing treatments for HIV and find out if we are getting closer to a cure.